Shopping Cart
Remove All
Your shopping cart is currently empty
Rivastigmine (Exelon) is a Cholinesterase Inhibitor, used for therapy of Alzheimer disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $47 | In Stock | - | |
| 50 mg | $55 | In Stock | - | |
| 100 mg | $81 | In Stock | - | |
| 200 mg | $108 | In Stock | - | |
| 500 mg | $135 | In Stock | - |
| Description | Rivastigmine (Exelon) is a Cholinesterase Inhibitor, used for therapy of Alzheimer disease. |
| Targets&IC50 | ChE:5.5 μM |
| In vivo | Preclinical biochemical studies indicates that rivastigmine has central nervous system selectivity over peripheral inhibition. It ameliorates memory impairment in rats with forebrain lesions. The drug is rapidly absorbed orally, with a bioavailability of 0.355 and low protein binding (40%). Its elimination halflife is less than 2 hours, and it is converted to an inactive metabolite at the site of action, bypassing hepatic metabolic pathways. Its disposition essentially is unaltered in patients with renal or hepatic impairment. It also has dosedependent effects on AChE inhibition[1]. |
| Cell Research | Chronic toxicity is assessed 7 days after continuous exposure of cells to donepezil or rivastigmine using cell viability and cell esterase activity and the estimated cell numbers as parameters for viability. Culture medium including the tested drugs is changed once after 4 days.(Only for Reference) |
| Synonyms | S-Rivastigmine, SDZ-ENA 713, Exelon |
| Molecular Weight | 250.34 |
| Formula | C14H22N2O2 |
| Cas No. | 123441-03-2 |
| Smiles | CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C |
| Relative Density. | 1.038g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 70 mg/mL (279.62 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.99 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.